710GO_Dosage, benefits & legal status
Also known as EMBC-710GO
An experimental weight-loss pill aimed at two melanocortin receptors instead of one, so far tested only in animals.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is 710GO?
Plain language first. The technical label stays, but it never stands alone.Overview
It pushes the brain's own fullness signal, the one setmelanotide boosts, but at two receptors with near-equal strength and in a form meant to be swallowed. In obese monkeys it cut weight by 11.8% against controls over 15 weeks, mostly fat. A phase 1 in about 100 people in Australia began in May 2026. Its sequence is undisclosed, and it is not approved anywhere.
710GO is an oral peptide agonist of the MC3 and MC4 melanocortin receptors, developed by Endevica Bio and now run by its 2026 spinout Kalohexis.
What it's used for
An experimental obesity pill from the melanocortin family. Monkey data only so far; the first human trial started in May 2026.
How does 710GO work?
What it does in the body, and where.710GO is a peptide built with non-standard amino acids and a C-terminal extension to survive the gut and avoid off-target receptors. Its sequence has not been published.
- 01Two receptors, equal weightIn cell assays it activated MC3R (EC50 0.073 nM) and MC4R (0.042 nM) almost equally. In the same table setmelanotide was about 15 times more potent at MC4R than at MC3R.
- 02Why add MC3RThe developers argue that MC3R activity spares lean mass and avoids the blood pressure rise seen with MC4R-focused drugs. In their monkeys 90% of the weight lost was fat, and setmelanotide raised night-time blood pressure where 710GO did not.
- 03By mouthMonkeys took it by mouth in saline. How it is absorbed, and how much reaches the blood, have not been disclosed.
Hits 2 receptors at once.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Monkey studies
Early research- Animal studyObese male monkeys given it by mouth for 15 weeks lost 11.8% of body weight against controls; 90% of the loss was fat and lean mass did not fall significantly.
- Animal studySix weeks after stopping, they had regained about a third of the lost weight.
- Animal studyAdded to semaglutide for 19 days, weight fell 7.6% against 4.1% on semaglutide alone, in 4 and 3 animals.
In people
Investigational- No dataA phase 1 in Australia started dosing in May 2026. No results, doses or registry number have been released.
- No dataThe authors note small groups, large variation between animals and male monkeys only.
Company releases quote 11.7% monkey weight loss at 13 weeks; the peer-reviewed figure is 11.76% against controls after 15 weeks of dosing in 10 monkeys. The semaglutide combination appears as 6.5% against 3.0% in releases and 7.6% against 4.1% in the paper. A '1.1% regain' figure has no primary source; the paper reports a third of lost weight returning within 6 weeks off drug. The published work is Endevica Bio's; Kalohexis is a 2026 spinout. It is the opposite of mifomelatide, the same company's drug that blocks these receptors to raise appetite.
The published record
Papers and trials about 710GO
1 papers tagged human · 1 not reviews or lab · 0 clinical trial publications
Furthest stage reached: No clinical trial on record
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about 710GO
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
Nothing published
How much, and do you cycle it?
The range, and whether you take breaks.No human dose disclosed, not established (daily in monkeys). No established pattern No range
Monkeys were dosed daily for up to 15 weeks, then stopped, and regained about a third of the lost weight within 6 weeks. No human schedule has been published.
Nothing publishedNo figure
The paper says only that 710GO and a sibling compound have similar pharmacokinetics; the data sit in a supplementary file that could not be read. Oral bioavailability has not been disclosed.
You can compare this against the whole library to see where it sits.
What does it cost?
Typical dose and cost, in plain numbers.710GO is not injected
It is taken by mouth (oral). No human dose has been disclosed for the phase 1. Monkeys received 10 to 30 mg/kg by mouth once daily, or 15 mg/kg twice daily, doses that do not translate to people. Any dose offered for it would be invented.
How do you store it?
Before mixing, and after.Room temperature. Cool, dry, out of light.
710GO is taken as a pill or capsule. Keep it in its original container at room temperature, away from heat, humidity, and direct sun. No fridge or mixing needed. Check the expiration date on the bottle.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Any use outside the phase 1: no human safety data have been published
- Pregnancy or breastfeeding
Stop and get help
- Not applicable outside the trial. No product exists and no human side-effect profile has been published
Common effects
- No human data have been published
- In monkeys: no change in blood pressure, heart rate or QT interval at oral doses up to 60 mg/kg, and no vomiting or diarrhoea
- Skin darkening and sexual effects, known with other melanocortin drugs, were not reported in the monkey paper
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is 710GO approved?
And where the numbers on this page come from.No. 710GO is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteBy mouth (oral)
- Checked12 October 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
Not approved anywhere. Kalohexis announced on 28 May 2026 that the first people had been dosed in a randomised, placebo-controlled phase 1 in Australia with single-dose, 28-day multiple-dose and food-effect parts, in about 100 healthy volunteers with overweight or obesity. No registry number or dose levels have been disclosed. Kalohexis filed a confidential draft IPO registration in July 2026. No INN, UNII or CAS has been assigned.
You can compare this against the whole library, or read how to check a seller.
If you're weighing 710GO, it's worth reading Adropin, AT-7687, and Irisin in the same class.
An experimental weight-loss pill aimed at two melanocortin receptors instead of one, so far tested only in animals.
- Dose
- No human dose disclosed
- How often
- Not established (daily in monkeys)
A metabolic hormone measured in blood, sold as though the measurement were a treatment.
- Dose
- Research only
- How often
- Not established
An experimental weekly shot that blocks the GIP receptor, the opposite of what tirzepatide does.
- Dose
- 25 or 50 mg weekly (phase 2 doses)
- How often
- Weekly
The exercise-in-a-pill myokine, and a decade-long argument about whether the tests for it work.
- Dose
- Research only
- How often
- Not established
Guides for this compound
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
- Semaglutide vs Tirzepatide vs Retatrutide
One receptor, two, or three. Mechanism, trial weight loss, side effects, and real cost.
Sources
- Seiler JL et al., Nature Communications 2026;17:4808(2026)Dual MC3R/MC4R agonist (EC50 0.073 and 0.042 nM). Obese male monkeys, 15 weeks oral: weight down 11.76 +/- 2.09% against vehicle (n=10 vs 4), 90% of it fat; a third regained 6 weeks off drug. With semaglutide over 19 days: 7.6% against 4.1%. No blood pressure, heart rate or QTc change up to 60 mg/kg.
- Kalohexis, first patients dosed in phase 1 (28 May 2026)(2026)Randomised, double-blind, placebo-controlled phase 1 with single-dose, 28-day multiple-dose and food-effect parts, about 100 volunteers with overweight or obesity, in Australia.
- Kalohexis, company launch (19 Mar 2026)(2026)Spun out of Endevica Bio. Quotes 11.7% monkey weight loss at 13 weeks and 6.5% against 3.0% with semaglutide, figures that differ from the paper.
- bioRxiv preprint 10.1101/2025.11.25.690554(2025)Earlier version of the monkey study; saline-treated animals gained 4.6%.
- Kalohexis, ObesityWeek 2026 poster announcement (7 Oct 2026)(2026)710GO still in phase 1; mouse data on lean-mass-sparing weight loss to be presented in November 2026.
- FDA GSRS search, 710GO(2026)No substance record.
Beyond these, 2 records are indexed. Browse the records